|
|
|
|
|
|
|
GTX Inc (GTXI)
|
|
19.33 -0.16 (-0.82%)
|
05-22 09:52
|
|
Open:
|
19.5
|
Pre. Close:
|
19.49
|
|
High:
|
19.62
|
Low:
|
19.11
|
|
Volume:
|
6,404
|
Market Cap:
|
465M
|
|
|
|
Stock Price Prediction (Update at 5:00pm est.)
|
|
If
tomorrow:
|
Open
lower
|
Open
higher
|
|
High:
|
20.497 - 20.579
|
20.579 - 20.658
|
|
Low:
|
18.765 - 18.852
|
18.852 - 18.935
|
|
Close:
|
19.349 - 19.487
|
19.487 - 19.619
|
|
|
|
Technical analysis (as of: 2018-05-21 4:29:51 PM)
|
|
Overall:
|
|
|
Stoxline posted a BUY today, same as yesterday. This stock seems to continue bullish move. If you bought, continue to hold stock until SELL signal. You are relatively safe to buy now, upward move is expected.
|
|
Target:
|
Six months: 23.90  One year: 27.92
|
|
Support:
|
Support1: 17.52 Support2: 15.70
|
|
Resistance:
|
Resistance1:
20.47 Resistance2: 23.90
|
|
Pivot:
|
17.62
|
|
Moving Averages:
|
MA(5): 18.27 MA(20): 17.52
MA(100): 16.43 MA(250): 11.10
|
|
MACD:
|
MACD(12,26):
0.22 Signal(12,26,9): -0.02
|
|
%K %D:
|
%K(14,3): 78.88  %D(3): 77.03
|
|
RSI:
|
RSI(14): 65.02
|
|
52-Week:
|
High: 23.4
Low: 2.73 Change(%): 346.0
|
|
Average Vol(K):
|
3-Month: 13540
10-Days 27856
|
|
|
|
|
|
★
Strong Sell
★★
Sell ★★★
Neutral
★★★★
Buy
★★★★★
Strong Buy
|
|
|
Price, moving averages and
Bollinger Bands
|
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.GTXI has closed above the upper band by 14.7%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 25.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
|
|
|
Headline News
|
|
2018-05-21T10:00:00-04:00
Your Daily Pharma Scoop: Abeona Presents Strong Data, Glaxo Nucala Treatment Benefit, Rocket Pharma's Gene Therapy Data
2018-05-18T15:23:31-04:00
GTx's enobosarm continues to demonstrate treatment effect in mid-stage SUI study
2018-05-18T14:00:00-04:00
GTx Updates Phase 2 Enobosarm Clinical Trial Results in Stress Urinary Incontinence at 2018 AUA Annual Meeting
2018-05-15T07:00:00-04:00
GTx Provides Corporate Update and Reports First Quarter 2018 Financial Results
2018-05-11T12:02:27-04:00
Key events next week - healthcare
2018-04-16T07:00:00-04:00
GTx to Present Phase 2 Enobosarm Clinical Trial Results in Stress Urinary Incontinence at a Podium Presentation at 2018 AUA Annual Meeting
2018-04-10T08:00:00-04:00
Your Daily Pharma Scoop: Acadia Sell-Off, Therapix Soars On Results, Menlo Setback
2018-04-09T07:52:15-04:00
GTx completes patient enrollment in a Phase 2 clinical trial of enobosarm in SUI
|
|
|
Financial Analysis
|
|
Growth
|
|
|
Growth measures the growth of both a company's revenue
and net income. it tells investors how fast a company is growing.
|
|
Profitability
|
|
|
Profitability measures a company’s ability to
generate earnings as compared to its expenses
and other relevant costs.
|
|
Solvency
|
|
|
Solvency measures a company's ability to meet its long-term debts.
Acceptable solvency ratios will vary from industry to industry.
|
|
Efficiency
|
NA
|
|
Efficiency measures the strength of a company's return on invested capital.
It can identify business that are better managed or not.
|
|
Click here to get more fundamental analysis.
|
|
